← Back to Screener
Vertex Pharmaceuticals Inc (VRTX)
Price$446.83
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-4.88%
Price vs S&P 500 (4W)3.97%
VGM Score51.01
Market Capitalization$108.72B
P/E Ratio (Annual)27.50x
All Metrics
P/CF (Annual)29.94x
Book Value / Share (Quarterly)$76.17
P/TBV (Annual)6.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.35%
Cash Flow / Share (Quarterly)$14.60
Price vs S&P 500 (YTD)-9.60%
Gross Margin (TTM)86.24%
Net Profit Margin (TTM)35.51%
EPS (TTM)$16.87
10-Day Avg Trading Volume1.37M
EPS Excl Extra (TTM)$16.87
Revenue Growth (5Y)14.10%
EPS (Annual)$15.32
ROI (Annual)21.05%
Gross Margin (Annual)86.24%
Net Profit Margin (5Y Avg)26.58%
Cash / Share (Quarterly)$28.51
P/E Basic Excl Extra (TTM)25.06x
Revenue Growth QoQ (YoY)7.82%
EPS Growth (5Y)8.28%
P/E Normalized (Annual)27.50x
ROA (Last FY)15.42%
Revenue Growth TTM (YoY)10.08%
EBITD / Share (TTM)$19.04
ROE (5Y Avg)17.12%
Operating Margin (TTM)38.31%
Cash Flow / Share (Annual)$12.57
P/B Ratio5.61x
P/B Ratio (Quarterly)5.87x
Net Income / Employee (Annual)$617,700
EV / Revenue (TTM)8.30x
Net Interest Coverage (TTM)72.37x
ROA (TTM)17.18%
EPS Growth QoQ (YoY)61.58%
EV / EBITDA (TTM)20.71x
EPS Incl Extra (Annual)$15.32
Current Ratio (Annual)2.90x
Quick Ratio (Quarterly)2.38x
3-Month Avg Trading Volume1.35M
52-Week Price Return0.68%
EV / Free Cash Flow (Annual)31.77x
P/E Incl Extra (TTM)25.06x
Revenue / Employee (TTM)$1,909,100
Tangible BV / Share (Quarterly)$71.82
P/S Ratio (Annual)9.06x
Asset Turnover (Annual)0.47x
52-Week High$507.92
Operating Margin (5Y Avg)31.29%
EPS Excl Extra (Annual)$15.32
CapEx CAGR (5Y)10.99%
Tangible BV CAGR (5Y)17.01%
26-Week Price Return3.05%
Quick Ratio (Annual)2.27x
13-Week Price Return-3.04%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)3.02x
Enterprise Value$101.47B
Revenue / Share Growth (5Y)14.57%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)17.07%
Revenue / Employee (Annual)$1,875,200
Inventory Turnover (Annual)1.14x
Pretax Margin (Annual)38.69%
Cash / Share (Annual)$26.02
3-Month Return Std Dev29.96%
Gross Margin (5Y Avg)87.10%
Net Income / Employee (TTM)$677,900
EBITDA CAGR (5Y)8.13%
EBITDA Interim CAGR (5Y)5.43%
ROE (Last FY)21.18%
Net Interest Coverage (Annual)16.95x
EPS Basic Excl Extra (Annual)$15.32
P/FCF (TTM)29.30x
Receivables Turnover (TTM)6.43x
EV / Free Cash Flow (TTM)27.35x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$16.87
Receivables Turnover (Annual)6.55x
ROI (TTM)23.89%
P/S Ratio (TTM)8.90x
Pretax Margin (5Y Avg)33.75%
Revenue / Share (Annual)$46.52
Tangible BV / Share (Annual)$71.56
Forward P/E22.27x
Free OCF CAGR (5Y)1.30%
Price vs S&P 500 (52W)-23.69%
P/E Ratio (TTM)25.06x
Year-to-Date Return-1.44%
5-Day Price Return1.92%
EPS Normalized (Annual)$15.32
ROA (5Y Avg)12.94%
Net Profit Margin (Annual)32.94%
Month-to-Date Return-0.16%
Cash Flow / Share (TTM)$13.94
EBITD / Share (Annual)$16.99
EPS Growth (3Y)6.12%
Operating Margin (Annual)34.77%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)25.64x
ROI (5Y Avg)16.60%
P/E Excl Extra (TTM)25.06x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$16.87
P/TBV (Quarterly)6.31x
P/B Ratio (Annual)6.16x
Inventory Turnover (TTM)1.08x
Pretax Margin (TTM)42.28%
Book Value / Share (Annual)$73.49
Price vs S&P 500 (13W)-11.29%
Net Margin Growth (5Y)-5.50%
Beta0.31x
P/FCF (Annual)34.04x
Revenue / Share (TTM)$47.67
ROE (TTM)23.93%
52-Week Low$362.50
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 264.47est. 4.40
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.05
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Inc | D | C | C | $446.83 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Vertex Pharmaceuticals is a global biotech company with a dominant position in cystic fibrosis treatments (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) and a diversified pipeline including approved gene-editing therapy Casgevy for blood disorders and Journavx for acute pain. The company is also advancing cell therapies for type 1 diabetes and small-molecule programs targeting APOL1-mediated kidney disease.